Roy S. Herbst, MD, PhD
Yale University
H-index: 144
North America-United States
Top articles of Roy S. Herbst, MD, PhD
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF. | Roy S Herbst Hendrik-Tobias Arkenau Emiliano Calvo Johanna C Bendell Nicolas Penel | 2020/5/20 | |
SWOG S1400A (NCT02154490): A phase II study of durvalumab for patients with previously treated stage IV or recurrent squamous cell lung cancer (Lung-MAP sub-study) | Clinical Lung Cancer | Hossein Borghaei Mary W Redman Karen Kelly Saima N Waqar Francisco Robert | 2020/11/10 |
IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). | Jacek Jassem Roy S Herbst Filippo de Marinis Jacques Cadranel Tibor Csőszi | 2020/5/20 | |
Abstract C115: Yale Cancer Disparities Firewall Project: Taking lifestyle change and cancer screening into the community to reduce cancer disparities | Beth A Jone Roy Herbst Sakinah C Suttiratana Monique Killins Denise Stevens | 2020/6/1 | |
VISTA/PSGL1 axis as a dominant immunomodulatory pathway in human non-small cell lung cancer | Alicia Ding Franz Villarroel-Espindola Adam Ducler Brian S Henick Shruti Desai | 2020/8/15 | |
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC | New England Journal of Medicine | Roy S Herbst Giuseppe Giaccone Filippo de Marinis Niels Reinmuth Alain Vergnenegre | 2020/10/1 |
Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA | J Clin Oncol | Roy S Herbst Masahiro Tsuboi Thomas John Christian Grohe Margarita Majem | 2020 |
Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy | Clinical cancer research | Yuting Liu Jon Zugazagoitia Fahad Shabbir Ahmed Brian S Henick Scott N Gettinger | 2020/2/15 |
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study | Journal of Clinical Oncology | Roy S Herbst Edward B Garon Dong-Wan Kim Byoung Chul Cho Jose L Perez-Gracia | 2020/5/10 |
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials | Clinical Radiology | AL Tam V Papadimitrakopoulou II Wistuba JJ Lee JE Ensor | 2021/2/1 |
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer. | Michael W Lu Guneet Walia Katja Schulze Michelle Yuri Doral Sophia L Maund | 2020/5/20 | |
Abstract B045: Operationalizing community engagement and participation: Experiences of the Yale Cancer Disparities Firewall Project to impact lifestyle change and cancer screening | Sakinah C Suttiratana Monique Killins Denise E Stevens Jose DeJesus Roy Herbst | 2020/6/1 | |
Assessment of the co-localization between PD-L1 positive macrophages and PD-1 positive cells is associated with benefit from PD-1 axis immunotherapy in NSCLC | Cancer Research | Yuting Liu Jon Zugazagoitia Kurt A Schalper Roy S Herbst David L Rimm | 2020/8/15 |
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer | New England Journal of Medicine | Yi-Long Wu Masahiro Tsuboi Jie He Thomas John Christian Grohe | 2020/10/29 |
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer | Journal of Thoracic Oncology | Roy S Herbst Hendrik Tobias Arkenau Johanna Bendell Edward Arrowsmith Martin Wermke | 2020/10/15 |
Longitudinal immunological analyses reveal inflammatory misfiring in severe COVID-19 patients | medRxiv | Carolina Lucas Patrick Wong Jon Klein Tiago BR Castro Julio Silva | 2020/6/24 |
Frontline immunotherapy for NSCLC—the tale of the tail | Nature Reviews Clinical Oncology | Anne C Chiang Roy S Herbst | 2020/2 |
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial | The Lancet Oncology | Sarah B Goldberg Kurt A Schalper Scott N Gettinger Amit Mahajan Roy S Herbst | 2020/4/3 |
Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). | Mary Weber Redman Vassiliki Papadimitrakopoulou Katherine Minichiello David R Gandara Fred R Hirsch | 2020/5/20 | |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study | The Lancet | Nicole M Kuderer Toni K Choueiri Dimpy P Shah Yu Shyr Samuel M Rubinstein | 2020/6/20 |
